The Food and Drug Administration's independent panel of experts decided on Wednesday against Biogen's ALS treatment efficacy. ALS medication is under consideration for a rare and aggressive type of illness. Tofersen is a medication that was created to treat a rare hereditary variant of amyotrophic lateral sclerosis or ALS. Three advisors supported effectiveness, five opposed it, and one abstained. Clinical Trial VALOR Data from the Phase 1/2/3 clinical trial VALOR support Biogen's application for accelerated approval of tofersen. (NCT02623699). The Phase 1 and 2 portions of the trial demonstrated that tofersen could lower SOD1 protein levels as intended, as well as that the medication was typically well tolerated. 108...

The Federal Reserve of the United States raised benchmark interest rates by 25 basis points. Not long ago, forecasters were split on whether the March meeting would see rates rise by 50 basis points or 25 basis points.  The latest bank crises forced the financial pundits to reassess their calculations, with the majority forecasting a 25 basis point increase and several publicly declaring that the Fed should push the pause button because the US banking system has yet to get its sea legs. What Does It Mean For Americans? The Federal Open Market Committee (FOMC) announced on March 22 that it has agreed to boost the target range for...

A self-proclaimed "crypto king" was allegedly kidnapped and tortured for days by attackers wanting a multi-million dollar ransom. Aiden Pleterski, 23, of Ontario, Canada, was...

Researchers are investigating how the eye can aid in the early detection of Alzheimer's disease. By the time memory and conduct are impacted, the...